Schiff base-forming compounds inhibit estrogen receptor-positive and -negative mammary carcinoma cell proliferation.

被引：0
|
作者：
Davis, BA [1 ]
机构：
[1] Virginia Polytech Inst & State Univ, Mol Nutr Lab, Blacksburg, VA 24061 USA
来源：
FASEB JOURNAL | 2001年 / 15卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A963 / A963
页数：1
相关论文
共 50 条
  • [21] The Clinical Significance of the Estrogen Receptor β Expression for Endocrine Therapy in Patients with ERα-negative and Progesterone Receptor-positive Breast Carcinoma
    Park, Min Ho
    Ryu, Hee Seon
    Ro, Hye Won
    Cho, Jin Seong
    Yoon, Jung Han
    Jegal, Yung Jong
    Kim, Jo Heon
    Lee, Ji Shin
    Park, Chang Soo
    JOURNAL OF BREAST CANCER, 2009, 12 (03) : 156 - 162
  • [22] Evaluation of the STAT3 inhibitor GLG-302 for the prevention of estrogen receptor-positive and -negative mammary cancers
    Shoemaker, Robert H.
    Fox, Jennifer T.
    Juliana, M. Margaret
    Moeinpour, Fariba L.
    Grubbs, Clinton J.
    ONCOLOGY REPORTS, 2019, 42 (03) : 1205 - 1213
  • [23] β-APO-carotenoic acids inhibit proliferation of estrogen receptor (ER) positive and ER negative breast tumor cell lines.
    Tibaduiza, EC
    Fleet, JC
    Clagett-Dame, M
    Krinsky, NI
    Russell, RM
    FASEB JOURNAL, 1998, 12 (05): : A813 - A813
  • [24] Mammary Adipose Tissue-Derived Lysophospholipids Promote Estrogen Receptor-Negative Mammary Epithelial Cell Proliferation
    Volden, Paul A.
    Skor, Maxwell N.
    Johnson, Marianna B.
    Singh, Puneet
    Patel, Feenalie N.
    McClintock, Martha K.
    Brady, Matthew J.
    Conzen, Suzanne D.
    CANCER PREVENTION RESEARCH, 2016, 9 (05) : 367 - 378
  • [25] Survivin Expression in Estrogen Receptor-Positive and Triple Negative Invasive Breast Carcinoma: Correlation with Clinicopathologic Features.
    Bohman, K. D.
    Cohen, C.
    Sullivan, H. C.
    Zbytek, B.
    Adams, A. L.
    MODERN PATHOLOGY, 2011, 24 : 28A - 28A
  • [26] Comparative Expression Profiles of E-Cadherin and Vimentin in Triple Negative and Estrogen Receptor-Positive Breast Carcinoma
    Swadley, M. J.
    Cohen, C.
    Sullivan, H. C.
    Williams, D. J.
    Taliaferro-Smith, L. D.
    Oprea, G. M.
    Adams, A. L.
    LABORATORY INVESTIGATION, 2012, 92 : 69A - 69A
  • [27] Comparative Expression Profiles of E-Cadherin and Vimentin in Triple Negative and Estrogen Receptor-Positive Breast Carcinoma
    Swadley, M. J.
    Cohen, C.
    Sullivan, H. C.
    Williams, D. J.
    Taliaferro-Smith, L. D.
    Oprea, G. M.
    Adams, A. L.
    MODERN PATHOLOGY, 2012, 25 : 69A - 69A
  • [28] Oestrogen withdrawal reduces cell proliferation only in oestrogen receptor-positive ductal carcinoma in situ
    Boland, GP
    McKeown, A
    Chan, KC
    Knox, WF
    Potten, CS
    Bundred, NJ
    BRITISH JOURNAL OF SURGERY, 2002, 89 (05) : 667 - 668
  • [29] BIOCHEMICALLY ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE BREAST-CARCINOMA - IMMUNOCYTOCHEMICAL HORMONE RECEPTORS AND PROGNOSTIC FACTORS
    KESHGEGIAN, AA
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 1994, 118 (03) : 240 - 244
  • [30] Short-term Prophylactic Tamoxifen Reduces the Incidence of Antiestrogen-Resistant/Estrogen Receptor-Positive/Progesterone Receptor-Negative Mammary Tumors
    Rose-Hellekant, Teresa A.
    Skildum, Andrew J.
    Zhdankin, Olga
    Greene, Amy L.
    Regal, Ronald R.
    Kundel, Katherine D.
    Kundel, Donald W.
    CANCER PREVENTION RESEARCH, 2009, 2 (05) : 496 - 502
12345